BW

11

Dic

By MetroLatinoUSA

BW

Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH

 --Preclinical data for Cimeio’s CD117- and CD123-shielded cells, and CD117 mAbs, demonstrate the potential of Cimeio’s SCIP platform to enable novel immunotherapy-based conditioning and post-transplant treatment approaches-- BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD117 and…

Leer más...

11

Dic

By MetroLatinoUSA

BW

OrBit Markets and Flowdesk Announce Partnership to Develop Treasury Management Solutions

SINGAPORE--(BUSINESS WIRE)--OrBit Markets, the leading institutional liquidity provider in digital asset options and structured products, today announced a strategic partnership with Flowdesk, a provider of trading infrastructure for market-making and other crypto financial services. After a rapid growth over the past two years, token issuers now face many challenges such…

Leer más...

11

Dic

By MetroLatinoUSA

BW

Ajax Therapeutics Presents Preclinical Data on AJ1-10502, a Next Generation Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting

– AJ1-10502 demonstrates enhanced selectivity and improved efficacy with significant reductions in mutant cell fraction, compared to the leading Type I JAK2 inhibitor, ruxolitinib, in multiple disease models of myeloproliferative neoplasms (MPNs) – NEW YORK--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel,…

Leer más...

11

Dic

By MetroLatinoUSA

BW

New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response, transfusion independence and splenic response in the majority of patients who responded to treatment during first 24 weeks Additional analyses from MOMENTUM suggest that transfusion independence at week 24 was associated with overall survival PHILADELPHIA--(BUSINESS WIRE)--#ASH2022--GSK…

Leer más...

11

Dic

By MetroLatinoUSA

BW

Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma

-- Treatment Sequencing Post Hoc Analysis of Outcomes in Patients Treated with Any Cellular Immunotherapy (Including Yescarta in Third-Line) Further Support Previously Reported ZUMA-7 Study Data Showing Benefit of Earlier, Second-Line Treatment with Yescarta -- -- Additional Analysis Reports Improved Outcomes with Yescarta Versus Standard of Care Across Both High…

Leer más...

11

Dic

By MetroLatinoUSA

BW

Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session

- INCA033989, a new anti-mutant calreticulin (CALR)-targeted monoclonal antibody, represents important research milestone in myelofibrosis (MF) and essential thrombocythemia (ET) - INCA033989 abstract selected as one of only six ASH plenary presentations - INCA033989 clinical trials to begin in 2023 - Research highlights Incyte’s discovery capabilities and progress of its…

Leer más...

11

Dic

By MetroLatinoUSA

BW

Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022

– Updated data from the Phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma (DLBCL) – – Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes,…

Leer más...

11

Dic

By MetroLatinoUSA

BW

Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis

– Kite’s Manufacturing Time for Yescarta® in the U.S. is Median of 7-Days from Start of Cell Enrichment to Harvest, with an Overall 16-Day Turnaround Time (Leukapheresis to Product Release) – – CIBMTR Analysis Finds Median ‘Vein-to-Vein’ Time (Leukapheresis to Infusion) in Real World Setting is 27-Days for Yescarta in…

Leer más...

11

Dic

By MetroLatinoUSA

BW

Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene autogedtemcel (nula-cel) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the…

Leer más...

11

Dic

By MetroLatinoUSA

BW

MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting

Detailed results from completed Phase 1b CIMON trial in 21 acute myeloid leukemia (AML) patients treated with the company’s Microbiome Ecosystem TherapyTM (MET) oral capsule, MaaT033, demonstrating its safety and ability to increase gut microbiota richness. Results of the study evaluating the tolerated dose of MaaT033 in patients with AML…

Leer más...